Other News

New Study Aims to Show Effectiveness of CRT-D Technology for Heart Failure Patients with Atrial Fibrillation

First Enrollments Underway for BIO-AffectDX Trial Evaluating Advanced, Two-Lead CRT-DX System LAKE OSWEGO, Ore., July 30, 2021 /PRNewswire/ — In association with Heart Rhythm 2021, BIOTRONIK today announced first enrollments in the landmark BIO-AffectDX trial, designed to evaluate clinical outcomes of cardiac resynchronization therapy (CRT) in patients with heart failure (HF) and atrial fibrillation (AF). BIO-AffectDX is a multi-center, observational study that will enroll HF […]

MindMics Announces Results from a Clinical Trial of Revolutionary Earbuds Technology — In-ear Infrasonic Hemodynography – to Achieve Cardiac Arrhythmia Assessment beyond that of ECG

Results Presented at the Heart Rhythm Society Meeting in Boston, July 30, 2021 CAMBRIDGE, Mass., Aug. 2, 2021 /PRNewswire/ – MindMics, Inc. reported results from the clinical trial of revolutionary earbuds that make use of a new technology — in-ear infrasonic hemodynography (IH) – for the monitoring of cardiac arrhythmias, resulting in insights beyond […]

Lexicon Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Clinical Update

Conference Call and Webcast at 8:00 am Eastern Time THE WOODLANDS, Texas, July 30, 2021 (GLOBE NEWSWIRE) — Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results for the three months ended June 30, 2021 and provided an update on key milestones. “We remain on track to submit our New Drug Application […]

Windtree Appoints Randall White, Ph.D., as Vice President, Clinical Program Management

WARRINGTON, Pa., Aug. 02, 2021 (GLOBE NEWSWIRE) — Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology and medical device company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today announced the appointment of Randall White, Ph.D., as Vice President, Clinical Program Management, reporting to Steve Simonson, M.D., […]

Artio Medical Successfully Completes Enrollment of First-in-Human Trial Investigating the Amplifi™ Vein Dilation System

Novel vein dilation system aims to improve vascular access for hemodialysis patients Prairie Village, KS – July 14, 2021 – Artio Medical, Inc., a medical device company developing innovative products for the peripheral vascular, neurovascular, and structural heart markets, announced today it has completed enrollment in its first-in-human study evaluating the […]

Baylis Medical Announces First Clinical Use of the VersaCross® Large Access Solution to Deliver Large Bore Therapy Solutions

TORONTO, July 29, 2021 /PRNewswire/ – Baylis Medical announced today the first clinical use of the VersaCross® Large Access Solution. The new solution includes the world’s first 3-in-1 RF wire paired with a seamless shapeable dilator designed to optimize tissue dilation for large sheath procedures, including left atrial appendage closure, transvenous mitral […]

Bardy Diagnostics Carnation Ambulatory Monitor Patch decreases both time to diagnosis and readmissions in Emergency Department patients with possible arrhythmia concerns in Clinical Study from Overlake Medical Center

BELLEVUE, Wash., July 29, 2021 /PRNewswire/ — A recent clinical study from Overlake Medical Center utilizing the Bardy Diagnostics Carnation Ambulatory Monitor (CAM) patch was presented at the 2021 Heart Rhythm Society (HRS) Conference. The abstract, “Accelerating Proper Evaluation of Emergency Department Patients for Arrhythmia Concerns with Discharge Use of ECG Patch Monitors,” […]

CryoLife Announces Sale of PerClot to Baxter

ATLANTA, July 29, 2021 /PRNewswire/ — CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that it has completed the sale of its PerClot product line to a subsidiary of Baxter International, Inc. (“Baxter”) (NYSE: BAX ), for up to $60.8 million in cash. Of the $60.8 million, CryoLife will receive […]

Biofourmis Earns FDA’s First-Ever Breakthrough Device Designation for a Novel Digital Therapeutic for Heart Failure

BiovitalsHF® Approved for Expedited FDA Review Process as a First-in-Class DTx for Heart Failure that Augments Traditional Guideline-Directed Medical Therapy BOSTON, July 29, 2021 /PRNewswire/ — Biofourmis, a Boston-based global leader in virtual care and digital therapeutics, announced today its BiovitalsHF® solution is the first-ever heart failure digital therapeutic to receive a Breakthrough Device […]